SRT Sartorius AG

EQS-News: Sartorius to advance drug discovery and manufacturing with AI in collaboration with NVIDIA

EQS-News: SARTORIUS AG / Key word(s): Alliance
Sartorius to advance drug discovery and manufacturing with AI in collaboration with NVIDIA (news with additional features)

16.05.2024 / 09:54 CET/CEST
The issuer is solely responsible for the content of this announcement.


Göttingen, Germany, May 16, 2024

Sartorius to advance drug discovery and manufacturing with AI in collaboration with NVIDIA
 
  • Exploring advanced technologies to help bring novel therapies to patients faster
  • Sartorius to leverage NVIDIA solutions used in live-cell imaging platforms in drug discovery, and predictive design of manufacturing processes, and more
  • Future plans include the creation of foundational models based on Sartorius’ extensive and unique data sets, as well as new predictive AI models, tools, and simulations
  • Dialogue with regulatory authorities on the use of AI in life sciences announced

The life science group Sartorius is expanding its multidisciplinary collaboration with NVIDIA to help enable the development of new and better therapies, combining Sartorius’ in-depth knowledge of life sciences and bioprocessing with NVIDIA’s AI-powered computing platforms and software.

"Biological interactions are exceptionally complex. Making better use of data by integrating life science expertise with AI solutions is a promising approach to simplify and accelerate biopharma drug discovery and manufacturing progress. This expanded collaboration with NVIDIA will help result in relevant technological innovations for our customers and ultimately for patients," said Prof. Dr. Oscar-Werner Reif, Chief Technology Officer of Sartorius.

Sartorius has been working with NVIDIA since 2020. The life science group has integrated NVIDIA's technology into its instruments, enabling edge computing applications of its live-cell imaging platform for commercialized AI assays in the lab. The focus of the collaboration has been on developing predictive AI models of stem cell-derived organoids to replace animal models in drug discovery and precision medicine. Sartorius is also using NVIDIA solutions for predictive bioprocess design and simulation tools for manufacturing innovative therapies.

The expanded collaboration includes increasing adoption of the suite of AI-powered computing platforms, software, and services in the Sartorius ecosystem. Plans involve creating and commercializing powerful foundational models based on Sartorius’ extensive and unique data sets. New predictive AI models, tools, and simulations for numerous application areas will also be available to Sartorius customers through the NVIDIA Clara suite and the .

In a forward-looking approach to innovation and technology integration in the biopharmaceutical sector, the collaboration will explore numerous advanced technologies, including the computer-based design and simulation of complex 3D-bioprinted spheroids and organoids or synthetic biological pathways and organisms designed based on Sartorius cell lines, to produce novel therapeutic agents and therapies.

A profile of Sartorius
Sartorius (XETRA: SRT3 | SRT) is a leading international partner of life sciences research and biopharmaceutical manufacturing. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies safely, rapidly, and economically. The company, based in Göttingen, Germany, has a strong global reach with around 60 production and sales sites worldwide. Sartorius regularly expands its portfolio through the acquisition of complementary technologies. In 2023, the company generated sales revenue of around 3.4 billion euros. Currently, around 14,600 employees are working for customers around the globe.

Visit our or follow us on .


Contact
Leona Malorny
Head of External Communications
7

 

Additional features:

File:


16.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com


Language: English
Company: SARTORIUS AG
Otto-Brenner-Straße 20
37079 Göttingen
Germany
Phone: +49.(0)551-308.0
Fax: +49.(0)551-308.3289
E-mail:
Internet:
ISIN: DE0007165607, DE0007165631
WKN: 716560 , 716563
Indices: DAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1904837

 
End of News EQS News Service

1904837  16.05.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1904837&application_name=news&site_id=research_pool
EN
16/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sartorius AG

Sartorius: 1 director

A director at Sartorius bought 400 shares at 173.350EUR and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...

Thomas J. Schiessle
  • Thomas J. Schiessle

CEO verlängert nicht über Nov. 2025 hinaus - Q1/24 dokumentierte opera...

Nach knapp 20 Jahren als hat CEO Dr. Joachim Kreuzburg angekündigt – aus Gründen der persönlichen Lebensplanung - keine nochmalige Vertrags­verlängerung - über den 30.11.25 hinaus – anzustreben; er strebe ferner keine operative Position in einem anderen Unternehmen an. Die Ankeraktionäre werden nun wichtig: Seit in 2023 ist Bio-Rad Laboratories Inc. Aktionär (derzeit Anteil an  Ord. 28%; Pref: 38%). Durch Lothar Kappich (SRT-AR-Vorsitz) wird die Horst Sartorius Erbengemeinschaft in Höhe von 50,0...

Thomas J. Schiessle
  • Thomas J. Schiessle

CEO will not extend beyond Nov. 2025 - Q1/24 documented operational tu...

After almost 20 years as CEO, Dr Joachim Kreuzburg has announced - for reasons of personal life planning - that he will not seek a further contract extension beyond 30.11.2025; furthermore, he will not seek an operational position in another company. The anchor shareholders are now becoming important: Bio-Rad Laboratories Inc. has been a shareholder since 2023 (current share in Ord. 28%; Pref: 38%). Lothar Kappich (SRT-SB-Chairman) represents the Horst Sartorius community of heirs in the amount ...

 PRESS RELEASE

EQS-News: Sartorius AG: After more than 20 years as CEO, Joachim Kreuz...

EQS-News: SARTORIUS AG / Key word(s): Personnel Sartorius AG: After more than 20 years as CEO, Joachim Kreuzburg will not pursue another term in office – Supervisory Board expresses great regret (news with additional features) 02.07.2024 / 10:53 CET/CEST The issuer is solely responsible for the content of this announcement.   Göttingen, July 2, 2024 Sartorius AG: After more than 20 years as CEO, Joachim Kreuzburg will not pursue another term in office – Supervisory Board expresses great regret The long-standing CEO of Sartorius AG, Dr. Joachim Kreuzburg, has informed the ...

 PRESS RELEASE

EQS-News: Sartorius AG: Joachim Kreuzburg strebt nach mehr als 20 Jahr...

EQS-News: SARTORIUS AG / Schlagwort(e): Personalie Sartorius AG: Joachim Kreuzburg strebt nach mehr als 20 Jahren als Vorstandsvorsitzender keine weitere Amtszeit an – Aufsichtsrat äußert großes Bedauern (News mit Zusatzmaterial) 02.07.2024 / 10:53 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Göttingen, 2. Juli 2024 Sartorius AG: Joachim Kreuzburg strebt nach mehr als 20 Jahren als Vorstandsvorsitzender keine weitere Amtszeit an – Aufsichtsrat äußert großes Bedauern Der langjährige Vorstandsvorsitzende der Sartorius AG, Dr. Joachim ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch